Clinical trial
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination…
NCT00299494 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00299494 |
|---|---|
| Title | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) |
| Official title | A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma |
| Lead sponsor | Pfizer, Industry |
| Collaborators | UCB Pharma Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | B-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | inotuzumab ozogamicin, Rituximab |
| Enrollment | 119 |
| Start date | May 4, 2006 |
| Primary completion | May 19, 2014 |
| Completion | Jun 2, 2014 |
| First posted | Mar 6, 2006 |
| Last update posted | Mar 8, 2018 |
| Countries | Australia, Belgium, France, Germany, Hong Kong, Italy, Netherlands, Poland, South Korea, Spain, Switzerland, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: